Introduction {#Sec1}
============

Immunomodulatory therapies lessen the disease burden of rheumatoid arthritis (RA) and may affect the risk of malignancy developing in these patients. An improved understanding of the links between RA and its treatment is essential in developing prevention and management strategies for malignancy risk mitigation in RA patients.

This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by either of the authors.

Malignancy Risk in RA {#Sec2}
=====================

Knowledge of the baseline risk of malignancy in patients with RA is important in order to assess the potential effect of immunosuppressive therapies on this risk. Evaluation of the risk of these therapies is made difficult because both the disease and the treatments may be associated with an overall increased risk of malignancy, or at least an increased risk of some forms of malignancy, in these patients. Immunosuppressant and immunomodulatory medication use is almost ubiquitous in RA treatment regimens due to the realization that untreated RA has severe disabling and potentially life-threatening consequences that are substantially mitigated by the use of these medications.

The overall malignancy risk in patients with RA is similar to that of the general population, as shown in one recent meta-analysis that found only a modest (5--10%) increase in overall malignancy in the former \[[@CR1]\]. Similar trends have been reported in other studies \[[@CR2]--[@CR4]\]. The cancer risks of patients with presumed low \[[@CR5]\] and high RA disease activity \[[@CR6]\] have been reported to be similar to those of the general population. Overall cancer risk has been reported to be especially high in patients with severe forms of RA, such as Felty syndrome (RA with splenomegaly and neutropenia) \[[@CR7]\].

The identification of risk factors for malignancy development can inform cancer prevention. In RA, cancer is associated with male sex \[[@CR8], [@CR9]\] and increased age \[[@CR9], [@CR10]\]. Compared to the general population, however, the effect of RA on cancer risk is more pronounced in the younger age groups \[[@CR4], [@CR8], [@CR11]\]. The highest cancer incidence in RA patients occurs in the first 5 years following RA diagnosis \[[@CR4], [@CR11]\], with decreasing risk over time \[[@CR11]\]. Inflammation \[[@CR12]\], often with increased white blood cell count \[[@CR13]\], is associated with malignancy in RA.

Incidence of Specific Malignancies in RA patients {#Sec3}
=================================================

Breast Cancer {#Sec4}
-------------

Although breast cancer is common in female patients with RA \[[@CR3]\], its occurrence appears to be lower than that in females in the general population \[[@CR1], [@CR8], [@CR14]\]. The reason for this is unclear, although women with RA have also been reported to have a borderline decreased risk of developing breast cancer even before being diagnosed with RA diagnosis \[[@CR15]\]. In spite of this general observation that women with RA have a lower risk of breast cancer, some sub-populations, including women under the age of 40 years \[[@CR8]\] and non-Caucasian women \[[@CR14]\], may be at increased risk. In addition, the prognosis of breast cancer in women with RA is worse than that in the general population \[[@CR16], [@CR17]\], with mortality increased by 40% \[[@CR17]\]. Knowledge of this risk underscores the importance of breast cancer screening in women with RA, which should be completed in conformity with existing guidelines according to age and presence of other risk factors, such as family history.

Cervical and Female Genital Cancers {#Sec5}
-----------------------------------

Rheumatoid arthritis-related disturbances of immune competence may hinder the clearance of pathogenic viruses, such as human papillomavirus (HPV). HPV persistence can transform cells and perpetuate cervical cancer \[[@CR18]\], which usually progresses in stages, from HPV+ and abnormal pap smears to cervical intraepithelial neoplasia (CIN) and eventually to invasive cervical cancer in untreated women. Abnormal pap smears may be more common in women with RA than in the general population \[[@CR19], [@CR20]\], but they are also associated with traditional risk factors, such as birth control use and a diagnosis of previous sexually transmitted disease \[[@CR21]\]. Although progression to pre-cancerous lesions (CIN) is accelerated in women with RA, studies of cervical cancer incidence have had mixed results \[[@CR22], [@CR23]\], and a meta-analysis \[[@CR1]\] showed no consistent trend in cervical cancer risk. Women with RA should undergo age- and conventional risk factor-specific cervical cancer screening.

Gastrointestinal Cancers {#Sec6}
------------------------

The incidence of gastric cancer in patients with RA appears to be lower than that in the general population \[[@CR3], [@CR6]\], but the former who are diagnosed with gastric cancer have a worse prognosis \[[@CR16]\]. Prevalence of liver cancer is similarly decreased \[[@CR3]\], with a worse prognosis \[[@CR16]\]. Liver cancer may be more prevalent in male and Hispanic patients \[[@CR8]\].

The incidence of colon cancer in RA patients is decreased compared to that of the general population \[[@CR1], [@CR3], [@CR4]\], while the incidence of rectal cancer is less clear \[[@CR1], [@CR3]\]. This trend in colon cancer has been attributed to increased non-steroidal anti-inflammatory drug (NSAID) use for pain and inflammation control in RA patients \[[@CR1], [@CR4], [@CR13]\]. Within the general population, NSAIDs have been found to correlate with a 30% decrease in colorectal cancer risk, but have no effect on survival after diagnosis \[[@CR24]\]. Although the effect of NSAID use on colon cancer incidence has not been directly studied in RA patients, there is likely a similar impact on colon cancer risk. Despite the decreased risk of colon cancer in patients with RA, for those diagnosed with colon cancer the prognosis is less favorable \[[@CR16]\].

Lung Cancer {#Sec7}
-----------

The incidence of lung cancer in patients with RA is generally reported to be increased compared to that in the general population \[[@CR1]--[@CR3], [@CR25], [@CR26]\], especially in men \[[@CR13]\], in those over 55 years of age, \[[@CR26]\] and in those with Felty syndrome \[[@CR7]\]. The risk of lung cancer in patients with RA prior to RA diagnosis is borderline decreased \[[@CR15]\], despite a markedly increased risk shortly after RA diagnosis \[[@CR15]\]. The survival prognosis for patients with RA who develop lung cancer is worse than that for the general population \[[@CR13], [@CR16]\]. Smoking is a risk factor for lung cancer mortality, with mortality decreasing after smoking cessation \[[@CR27]\].

Lymphoproliferative Malignancies {#Sec8}
--------------------------------

The risk of developing lymphoproliferative malignancies, including Hodgkin and non-Hodgkin lymphoma (NHL), is increased in patients with RA \[[@CR1]--[@CR5], [@CR11], [@CR28], [@CR29]\]. Patients with RA and NHL have an overall survival rate similar to that of patients in the general population with NHL, but lymphomas of the former are more likely to be low grade and mortality less likely to be lymphoma-related \[[@CR30]\]. Risk factors for lymphoma in RA patients are similar to those in the general population, including male sex \[[@CR8], [@CR11], [@CR31]\] and increased age \[[@CR3], [@CR31]\]. Hispanic patients with RA have an increased magnitude of lymphoma risk \[[@CR8]\].

The percentage of Epstein--Barr virus (EBV)+ lymphoma cases is generally similar in the RA population to that in the general population \[[@CR32]--[@CR34]\], although one study did observe an increased prevalence of EBV+ lymphomas in RA patients \[[@CR35]\]. Histologically, diffuse large B cell lymphoma (DLBCL) is the most frequent type of lymphoma in patients with RA, with an increased risk of between 50 and 200% \[[@CR5], [@CR29], [@CR32]\]. Compared to survival with other histological types, a diagnosis of DLBCL correlates with decreased survival \[[@CR32], [@CR35]\]. Most DLBCL is of the germinal center (GC) type \[[@CR28], [@CR36]\], but activated B cell (ABC) type has a worse prognosis \[[@CR36]\] and is more likely to constitute disseminated disease \[[@CR36]\]. All types of DLBCL are associated with RA disease activity \[[@CR34], [@CR36]\]. In addition, clonality of the immunoglobulin heavy chain has been associated with decreased survival in patients with DLBCL \[[@CR35]\].

Three theories have been proposed in attempts to explain increased lymphoma risk in RA patients. The first is that a common genetic predisposition links RA and lymphoma \[[@CR15]\]. This is unlikely, as first-degree relatives \[[@CR37]\] and patients before RA diagnosis \[[@CR15]\] do not have an increased risk of lymphoma. The second theory is that lymphomas arise in RA due to iatrogenic immunosuppression, allowing immunogenic tumors to develop. However, the increasing use of immunosuppressants is not correlated with an increased or decreased lymphoma rate in RA patients; i.e. the lymphoma rate in these patients has remained unchanged \[[@CR15], [@CR29], [@CR33], [@CR37]\], and the risk of lymphomas before the widespread use of aggressive immunosuppressants (1965--1984) remains comparable to risk today \[[@CR32]\]. Immunosuppressant use is widely believed to be a confounding factor in malignancy development, as the disease activity and severity RA largely correlates with immunosuppressant use.

The development of lymphoma in patients with RA is most likely due to the underlying RA disease pathobiology. Up to the seventh decile of RA disease activity, there is a minimal increased risk of lymphoma, but those in the top 20% of disease activity have a markedly heightened risk of lymphoma \[[@CR34]\]. Physicians should be watchful for lymphoma development in patients with RA who have high cumulative disease activity, or a Disease Activity Score-28 for Rheumatoid Arthritis of \>5.7 \[[@CR34]\]. While immunosuppressive treatment itself may cause some lymphomas, better control of disease activity appears to negate this increased risk \[[@CR33]\]. This potential double-edged sword underscores the need for optimal, but not overzealous immunosuppression in the treatment of RA.

The risk of multiple myeloma in patients with RA is about the same as in the general population. The authors of one meta-analysis commented that although there is serious heterogeneity among studies, the highest quality studies do not reflect an increased risk of multiple myeloma in RA patients \[[@CR38]\].

Skin Cancers {#Sec9}
------------

The effect of RA on development of skin cancer incidence is unclear. The largest study to date noted no increased risk of melanoma in biologic-naïve patients with RA \[[@CR39]\], although other studies have shown mixed results \[[@CR1], [@CR8], [@CR40]\]. The risk of non-melanoma skin cancer (NMSC) has been reported to be both increased \[[@CR41]\] and decreased \[[@CR11]\] in RA patients, and the prognosis for squamous cell carcinoma may be worse \[[@CR16]\]. The development of NMSC may be associated with the use of certain immunosuppressive medications, including tumor necrosis factor (TNF) inhibitors \[[@CR41]--[@CR44]\] and methotrexate \[[@CR45]\].

Other Cancers {#Sec10}
-------------

The incidence of prostate cancer is probably not increased in men with RA, although study results are mixed \[[@CR1]\]. Men with RA who develop prostate cancer appear to have a decreased time to mortality and a 50% increased mortality \[[@CR17]\]. Renal cell carcinoma has been reported in patients with RA and may confer an increased mortality, but it is not clear if risk is actually increased \[[@CR13]\].

Traditional Disease-Modifying Antirheumatic Drugs: Therapeutics and Cancer Risk {#Sec11}
===============================================================================

Immunosuppressive medications effectively control RA symptoms. Iatrogenic cancer risk is of major concern in RA, but assessment of this risk is confounded by lack of comparable control groups, as risk assessments from the general population, or even patients with less severe RA, can misinform risks. Because the great majority of patients with RA have received some type of therapy during their disease course, cancer risk studies on traditional disease-modifying antirheumatic drugs (DMARDs) generally compare malignancy risk in this patient population to that of the general population, or the risk of cancer in RA patients receiving agents not associated with increased risk, such as hydroxychloroquine or sulfasalazine \[[@CR46]--[@CR48]\]. In addition, disparate results have emerged from randomized controlled trials (RCTs) and population-based cohort studies, largely due to differences in populations and biases. In particular, many early RCTs enroll patients with severe disease that is not effectively controlled by medications. These patients, though randomized, are followed for relatively short periods of time, allowing minimal ascertainment of long-term risk. In population-based cohort studies, medication usage is not random, and certain medications are favored for patients with more severe disease. Although follow-up is usually longer and results more representative of the broad range in RA activity (from mild to severe disease), confounders cannot be entirely accounted for.

Azathioprine {#Sec12}
------------

Azathioprine may increase the risk of lymphoproliferative and a number of other malignancies in patients with RA \[[@CR25], [@CR49], [@CR50]\]. Since this medication is usually reserved for patients with severe disease, these findings are likely to be confounded by disease severity \[[@CR40]\].

Cyclophosphamide {#Sec13}
----------------

Cyclophosphamide is usually reserved for severe extra-articular manifestations of RA \[[@CR40]\], especially vasculitis and scleritis. This medication increases the risk of a number of malignancies, including hematologic malignancies \[[@CR50]\] and urinary tract and bladder cancer \[[@CR51], [@CR52]\]. The authors of one study noted that bladder cancer occurred in 25% of patients receiving a cumulative dose of \>80 g cyclophosphamide. This observation, as well as the declining incidence of severe extraarticular disease with overall improved disease management in recent decades, has led to this medication being used less frequency and then often and primarily for shorter durations in cases of life- or organ-threatening disease \[[@CR51]\]. Hydration and mesna use can be implemented to attempt to decrease these risks \[[@CR51]\].

Glucocorticoids {#Sec14}
---------------

Tapered doses of glucocorticoids are very effective in controlling inflammatory activity, but also confer considerable side effects. It has been reported that the use of glucocorticoids is associated with an increased incidence of malignancy in RA patients \[[@CR2], [@CR10]\]. A study of veterans with RA showed glucocorticoid use to be a risk factor for NMSC \[[@CR53]\]. However, all of these studies are confounded by RA disease activity. Overall, glucocorticoids do not increase malignancy risk.

Generally, glucocorticoid use appears to decrease lymphoma risk \[[@CR28], [@CR34], [@CR42], [@CR54]\], consistently among different disease severities \[[@CR54]\]. Oral glucocorticoid use of \<2 years has no impact on lymphoma risk, whereas longer glucocorticoid treatment regimens may decrease lymphoma risk \[[@CR54]\]. Steroid treatment does not alter clinical presentation or time course of lymphoma \[[@CR54]\].

Leflunomide {#Sec15}
-----------

Although few studies have been conducted to assess the effect of leflunomide on cancer risk in RA patients, in vitro studies have shown that, like azathioprine, methotrexate and cyclophosphamide, leflunomide may have some anti-neoplastic activity against multiple cancer types \[[@CR55]--[@CR58]\]. One recent study found a threefold increased risk of pancreatic cancer in patients with RA treated with leflunomide. This result was not reproduced in an analysis of patients from the UK and Sweden, although the datasets did show a trend toward an increased risk \[[@CR59]\].

Methotrexate {#Sec16}
------------

Methotrexate may have no effect on \[[@CR2]\] or may increase \[[@CR43], [@CR45]\] cancer risk, specifically melanoma, NHL and lung cancer \[[@CR45]\]. Reports of its effect on the development of lymphoproliferative disease are mixed. Some hematologic malignancies (between 27 \[[@CR60]\] and 90% \[[@CR61]\]) spontaneously regress between 2 and 5 months \[[@CR35], [@CR61]--[@CR63]\] after methotrexate withdrawal in patients with RA \[[@CR35], [@CR60]--[@CR64]\]. Results from population-based studies suggest that methotrexate does not increase the incidence of lymphoproliferative cancers over the baseline incidence in RA patients \[[@CR9], [@CR28], [@CR49], [@CR63], [@CR64]\]. In one study the incidence of lymphomas in patients with RA with or without methotrexate was similar, except that lymphomas developed sooner in those receiving methotrexate and some patients regressed upon methotrexate withdrawal \[[@CR60]\]. Although methotrexate seems to contribute to the growth of some lymphomas, it does not appear to increase their overall incidence \[[@CR35]\].

Methotrexate may have divergent effects on lymphoma development, decreasing the development of some lymphomas via decreased RA-related immunologic activity (which is linked to lymphoma development \[[@CR34], [@CR42]\]) and promoting other lymphomas through immunosuppression \[[@CR63]\], leading to an overall null impact on incidence. Methotrexate-induced lymphomas likely represent a small minority of lymphomas in RA patients \[[@CR49], [@CR63]\].

The majority of lymphoma cases are DLBCL, although diverse histologic patterns have been observed \[[@CR35], [@CR61]--[@CR64]\]. DLBCL is associated with a worse prognosis and is less likely to regress with methotrexate withdrawal \[[@CR35]\]. Lymphoma-specific survival was found not to differ based on methotrexate usage, but prognosis was worse than for lymphoma in the general population \[[@CR60]\].

Lymphoma treatment in the setting of RA with methotrexate use is complicated. Survival is similar among patients in whom methotrexate is withdrawn and those receiving chemotherapy \[[@CR64]\]. The authors of some studies advise watchful waiting up to 3 months after methotrexate withdrawal before starting the patient on chemotherapy, especially if the lymphoma is associated with EBV positivity and monoclonality \[[@CR61], [@CR63]\]. Methotrexate withdrawal is preferred to immediate chemotherapy when there is a good prognosis, single lesion and low risk of fast progression---but not in young patients with a high serum lactate dehydrogenase levels and poor risk status \[[@CR64]\]. Lymphocyte recovery 2 weeks after methotrexate withdrawal has shown promising preliminary results as a predictor of response \[[@CR61]\]. After cancer remission, glucocorticoid therapy and/or DMARD therapy with sulfasalazine and hydroxychloroquine are the preferred RA treatments if possible \[[@CR64]\] as the impact of restarting methotrexate on subsequent lymphoma development is uncertain \[[@CR61]\]. It is not clear which of the biologic and small molecule inhibitor medications may be preferred in patients with refractory disease, although TNF inhibitors are generally avoided.

Rituximab {#Sec17}
---------

Rituximab is a B cell-depleting antibody against CD20 that has not been reported to affect malignancy risk in RA patients \[[@CR65]\]. Rituximab has also been effectively used in the treatment of B-cell lymphomas in patients with RA \[[@CR66]\], serving as a single intervention to help control RA disease activity and prevent lymphoma growth and development \[[@CR62]\].

TNF Inhibitors {#Sec18}
--------------

Tumor necrosis factor alpha (TNF-α) facilitates both tumor cell death and cancer-promoting inflammation \[[@CR67]\]. Despite immense interest, an answer to the question of what precisely is the effect of TNF inhibitors on cancer risk in RA patients has been illusive due to the rarity of cancer events \[[@CR68]\].

There are five Federal Drug Administration-approved TNF-α inhibitors available in the USA---three monoclonal antibodies (adalimumab, golimumab and infliximab), a pegylated Fab fragment (certolizumab) and a soluble receptor fusion protein (etanercept). Although the results of early RCTs on TNF inhibitors suggested a dose-dependent increase in overall cancer \[[@CR69], [@CR70]\], more recent diverse studies, including both population-based and prospective studies, have failed to confirm this result \[[@CR2], [@CR57], [@CR71]--[@CR78]\]. It is possible that this difference is the result of an increased disease severity in patients enrolled in the RCTs compared to the general population or that it is secondary to biased prescribing; i.e. patients with a high cancer risk may forgo TNF inhibitors, thus biasing population-based studies. Patients with RA taking TNF inhibitors and DMARDs have a similar cancer stage at diagnosis \[[@CR79]\] and a similar mortality rate \[[@CR71]\] and malignancy recurrence rate \[[@CR12]\]. There do not appear to be major differences in individual TNF inhibitors in terms of cancer risk \[[@CR80]\].

Individual cancer types vary in incidence, with some data suggesting an increase in NMSC in RA patients taking TNF-α inhibitors \[[@CR43], [@CR44], [@CR73], [@CR74]\]. Although several studies have also suggested an increase in melanoma with TNF-α inhibitors \[[@CR43], [@CR44], [@CR76]\], the largest study to date, involving 48,304 patients with RA taking TNF inhibitors from 11 European biologics registrars, noted no increased risk, with an incident rate ratio of 1.1 (95% confidence interval 0.8--1.6) compared to biologic-naïve patients \[[@CR39]\]. A few studies have noted other variations in cancer risk, including an increased risk in colon cancer in RA patients taking TNF inhibitors \[[@CR68], [@CR81]\] compared to patients with RA not taking TNF inhibitors, but the risk overall is similar to that in the general population. Ovarian cancer is possibly increased \[[@CR81]\], while risk of female breast cancer has been reported to be decreased \[[@CR72]\]. One recent retrospective study observed that patients with RA treated with etanercept had a decreased cancer risk, but the results may have been subject to channeling bias and some bias secondary to study exclusion criteria \[[@CR57]\].

Although a number of studies have reported a positive correlation between TNF inhibitor use and lymphoma in RA \[[@CR9], [@CR68], [@CR75]\], the majority of studies have failed to reproduce that association \[[@CR31], [@CR43], [@CR67], [@CR76]\]. Confounding factors, specifically RA disease activity, might be responsible for the results of these positive studies. Since TNF inhibitors are normally given to patients with moderate to severe RA \[[@CR31]\], and increased disease activity has been shown to strongly correlate with lymphoma risk \[[@CR34], [@CR42]\], it is possible that populations of patients chosen to receive TNF inhibitors for their RA might have an apparently increased lymphoma risk secondary to their disease activity and not due to these medications \[[@CR68]\].

The majority of studies have detected an increased risk of NMSC \[[@CR41]--[@CR44]\] and possibly melanoma \[[@CR42], [@CR43], [@CR76], [@CR82]\] with TNF inhibitor treatment in RA patients, but others have reported no difference in risk with TNF inhibitors. On balance it would appear that melanoma risk is not increased with their use \[[@CR72], [@CR81], [@CR83]\]. Male \[[@CR82]\] and Caucasian \[[@CR83]\] patients with RA on TNF inhibitors may be at the greatest risk for these skin cancers; consequently, these patients should undergo regular screening for skin cancer \[[@CR44], [@CR83]\].

Other Biologics and Small Molecule Inhibitors {#Sec19}
---------------------------------------------

Cancer risk information for these therapeutics is scarce. Tocilizumab, an antibody against the interleukin-6 cytokine receptor, has not been associated with an increased risk for overall malignancy \[[@CR84], [@CR85]\]. Tofactinib, a small molecule Janus kinase inhibitor \[[@CR86], [@CR87]\], and abatacept, a fusion immunologlobulin targeting CTLA-4 \[[@CR1], [@CR78], [@CR88]\], have not been associated with increased malignancy risk, but these medications have not been used in as many patients or for as long as some of the TNF inhibitors.

Cancer Outcomes {#Sec20}
===============

Patients with RA have worse cancer mortality \[[@CR13], [@CR89]\] and prognosis \[[@CR16], [@CR17], [@CR25], [@CR89]\] and may be more likely to have metastatic disease \[[@CR17]\]. Worse survival is seen for hematopoetic malignancies \[[@CR25]\], squamous cell carcinoma \[[@CR16]\], upper aerodigestive tract cancers \[[@CR13], [@CR16], [@CR25]\], gastrointestinal cancers \[[@CR16]\] and liver \[[@CR16]\] prostate \[[@CR17]\] and breast cancer \[[@CR16], [@CR17]\] when diagnosed in the setting of RA. RA diagnosis appears to have more of an impact on mortality in lower stage cancer, with little impact on stage 4 cancers \[[@CR89]\] (Table [1](#Tab1){ref-type="table"}).Table 1Risk status for specific cancer types in patients with rheumatoid arthritisCancer typeRisk in general rheumatoid arthritisPrognosisImpact of therapeuticsRecommendations \[[@CR95]\]Overall10% increase \[[@CR1]\]Worse \[[@CR13], [@CR16], [@CR17], [@CR25], [@CR89]\]Follow national guidelinesBreastDecreased \[[@CR1], [@CR8], [@CR14]\]Worse \[[@CR16], [@CR17]\]Decreased with TNFi \[[@CR72]\]45--55 years of age: Annual mammography\>55 years of age: annual or biannual mammographyCervicalLikely unchanged \[[@CR1]\]21--29 years of age : Pap smear every 3 years30--65 years of age: Pap smear and HPV test every 5 years, or Pap smear every 3 yearsGastricDecreased \[[@CR3], [@CR6]\]Worse \[[@CR16]\]LiverDecreased \[[@CR3]\]Worse \[[@CR16]\]ColonDecreased \[[@CR1], [@CR3], [@CR4]\]Worse \[[@CR16]\]NSAIDs may inhibit tumorigenesis \[[@CR24]\]TNFi may restore general population level risk \[[@CR68], [@CR81]\]Annual (gFOBT or FIT) or triannual (Multitarget Stool DNA test) stool testing or flexible signmoidoscopy every 5 yearsColonoscopy every 10 years or after any positive testsLungIncreased \[[@CR1]--[@CR3], [@CR25], [@CR26]\]Worse \[[@CR13], [@CR16], [@CR25]\]May be increased with MTX \[[@CR45]\]Smoking cessation counseling, as appropriateConsideration of pulmonary imaging risks and benefitsLymphoproliferativeIncreased (2×) \[[@CR1]--[@CR5], [@CR11], [@CR28], [@CR29]\]Worse \[[@CR25]\]Increased with Aza, CYC \[[@CR50]\]Maybe prevented with diligent glucocorticoid use \[[@CR54]\]Potential to treat B cell lymphomas with RTX \[[@CR62], [@CR66]\]Control ofrheumatoid arthritis disease activity is importantMultiple myelomaLikely unchanged \[[@CR38]\]Non-melanoma skin cancerLikely unchanged \[[@CR11], [@CR41]\]Worse for SCC \[[@CR16]\]May be increased with TNFi \[[@CR43], [@CR44], [@CR73], [@CR74]\]Potential for skin cancer screening, depending on risk factorsMelanomaLikely unchanged \[[@CR39]\]Maybe increased with MTX \[[@CR45]\]ProstateLikely unchanged \[[@CR1]\]Worse \[[@CR17]\]Informed decision about prostate-specific antigen screening in menRenal cell carcinomaUnclear \[[@CR13]\]Worse \[[@CR13]\]*Aza* Azathioprine, *CYC* cyclophosphamide, *FIT* fecal immunochemical test, *HPV* human papillomavirus, *gFOBT* guaiac-based fecal occult blood test,*MTX* methotrexate, *NSAIDs* non-steroidal anti-inflammatory drugs, *RTX* rituximab, *SCC* squamous cell carcinoma, *TNFi* tumor necrosis factor inhibitor

Patients with Previous Cancers {#Sec21}
==============================

Studies evaluating previous cancer diagnosis in RA are scarce. The majority of these are specific to TNF inhibitors and caution against their use in patients with previous malignancy \[[@CR90]\] for 5--10 ten years after malignancy diagnosis \[[@CR91]\]. Female patients with RA in remission from breast cancer have been reported to have an equal recurrence rate regardless of TNF inhibitor usage \[[@CR91], [@CR92]\] or methotrexate use, although the use of thiopurines correlated with an increased recurrence rate \[[@CR92]\]. A similar finding was observed for patients with head and neck \[[@CR93]\], cervical \[[@CR94]\], or overall cancer in remission \[[@CR90]\], with the possible exception of melanoma \[[@CR90]\]. Overall, the use of DMARDs, both biologic and conventional, in patients with RA in cancer remission is understudied. There does not appear to be a significantly increased risk of cancer recurrence in patients on biological therapy.

Current State of Cancer Management and Screening in RA {#Sec22}
======================================================

In patients with RA without a previous cancer diagnosis, additional screening beyond the nationally recommended guidelines is not required prior to start of systemic therapy \[[@CR77]\]. In all patients with RA, usual age- and sex-appropriate cancer screening should be pursued, possibly with more frequent screening for skin cancer (Table [1](#Tab1){ref-type="table"}). In general, national guidelines (recently reviewed in \[[@CR95]\]) are appropriate for patients with RA. In the USA, mammograms are recommended in female patients over 45 years of age for early breast cancer detection. Pap smears and human pappillomavirus vaccination should be used as preventive measures for cervical cancer in female patients aged between 21 and 65 years. The risks and benefits of prostate cancer screening should be considered in men independent of their RA status. Colon cancer screening, including annual or triannual stool tests and colonoscopy every 10 years, is an appropriate therapeutic strategy for patients with RA. Unlike in the general population, in patients with RA, control of RA disease activity via immunosuppressive agents may decrease cancer risk, and thus RA disease activity should be well controlled. To date, no studies have specifically looked at the risks and benefits of increased skin cancer screening in patients with RA, but such screening may be a reasonable addition, especially in individuals with otherwise an increased skin cancer risk. Although the use of chest X-ray to detect lung cancer has not been studied in patients with RA, chest X-rays may be valuable for some patients with an especially high risk for lung cancer, specifically those with a significant smoking history (\>30 pack-years). Smoking cessation should be a primary objective in these cases.

Regarding DMARD use in patients with a cancer diagnosis, the 2015 American College of Rheumatology guidelines \[[@CR96]\] provide some guidance for specific medication usage in patients with pre-existent cancer. In the case of previous solid malignancy, the use of conventional DMARDs is preferred over biologics, but supportive evidence for these recommendations is weak. In the case of previous lymphoproliferative malignancy, rituximab or a combination of conventional DMARDs with abatacept or tocilizumab is preferred over TNF inhibitors. The role of rituximab as a dual agent to both control RA disease activity and lymphoma progression has been suggested and may be an optimal therapeutic in some cases \[[@CR62], [@CR66]\].

Conclusions {#Sec23}
===========

Malignancy is a major comorbidity in patients with RA and is related both to the disease and its treatment. Patients with RA appear to be at an increased risk of lung cancer and lymphoma, while the risk of colorectal and breast cancer is lower. Control of the underlying disease is critical to reducing cancer risk in RA patients. Vigilant cancer screening according to age- and sex-specific guidelines is important in RA management.
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